Technical analysis of Cellectar Biosciences, Inc. (CLRB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Price Performance
| 1 month | -9.27% |
| 3 months | -15.77% |
| Year-to-date | -20.34% |
| 1 year | -53.56% |
| 3 years | -96.31% |
52-Week Range
| 52-week High | $6.52 |
| 52-week Low | $2.20 |
| Avg Volume (90d) | 116K |
Technical Indicators
| SMA 50 | $2.52 |
| SMA 200 | $2.91 |
| Beta | 0.40 |
| 30-day Volatility (annualised) | 29.2% |
| Price vs SMA 50 | -6.8% |
| Price vs SMA 200 | -19.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.39 | |
| 2025-11 | $3.59 | +5.9% |
| 2025-12 | $2.95 | -17.8% |
| 2026-01 | $3.22 | +9.2% |
| 2026-02 | $3.25 | +0.9% |
| 2026-03 | $2.54 | -21.8% |
| 2026-04 | $2.60 | +2.4% |
| 2026-05 | $3.14 | +20.8% |
| 2026-06 | $2.78 | -11.5% |
| 2026-07 | $2.57 | -7.6% |
| 2026-08 | $2.51 | -2.3% |
| 2026-09 | $2.35 | -6.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $2.35 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.98 |
| EV / EBITDA | 0.59 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 6.66 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -28.56 |